IL2, a well‐characterized pleiotropic cytokine, plays crucial roles in immune response, and is one of the early immunotherapy drugs approved by the U.S. Food and Drug Administration for metastatic cancer.[17] A recent study revealed that IL2 promotes a tumor‐infiltrating CD8+ T‐cell response.[18]. This evidence concerns the gene CD8A and metastatic malignant neoplasm.